The National Review of Asthma Deaths (NRAD) came out a decade ago, yet as a nation, we still have the highest asthma death rate in Europe - four times that of Italy or the Netherlands. This is unsurprising, considering many patients still rely on their blue inhalers alone.However:• Blue inhalers don’t treat inflammation• Brown inhalers don’t relieve symptoms quicklyFirst and foremost, the best inhaler is the inhaler the patient will use and identifying what this is should actively involve the patient.
New BTS/SIGN/NICE Guideline on Asthma: diagnosis, monitoring and chronic asthma management 2024
This is a high-level summary of what the new BTS/NICE/SIGN Asthma: diagnosis monitoring and chronic asthma management guideline means for you as a primary healthcare professional and what steps you need to take to implement it effectively.
This article has been created as a summary of a range of material from PCRS tools and encompasses the basics of a good respiratory review.
The PCRS Integrated Care Board (ICB), Health Board and Trust toolkit aims to support healthcare commissioners across the UK to implement the new BTS/NICE/SIGN asthma guideline effectively and ensure the best possible care and outcome for all their asthma patients.
Over the past 20-years, there has been an increased focus on the use of newer biologic medication in people with severe asthma that is not controlled with usual asthma medication. Although there are currently six biologics (January 2025) licensed for use in severe asthma, estimates suggest that of the 60,000 people potentially eligible for biologics in England, only 8,000-10,000 are on these treatments.
Now is the time to make MART moves for asthma. We have been using the separate blue (reliever) and brown (preventer) inhalers for far too long. The National Review of Asthma Deaths (NRAD) came out a decade ago, yet as a nation, we still have the highest asthma death rate in Europe. This is unsurprising, considering many patients still rely on their blue inhalers alone. However,
You may also be interested in...
ARC is a global social movement created by the International Primary Care Respiratory Group (IPCRG) to drive change and disrupt the status quo in asthma management.
The mMRC (Modified Medical Research Council) Dyspnoea Scale is used to assess the degree of baseline functional disability due to dyspnoea.
The PCRS Greener Respiratory Healthcare Quality Improvement (QI) toolkit has been developed to support HCPs working in the primary care setting to understand and evaluate the environmental impact of their clinical practice, identify ways to reduce this impact, set goals and priorities and evaluat
Self-reported during community pharmacy consultations in London